Back to Search Start Over

The role of splenectomy in management of splenic B-cell lymphomas.

Authors :
Archibald, William J.
Baran, Andrea M.
Williams, AnnaLynn M.
Salloum, Rabih M.
Richard Burack, W.
Evans, Andrew G.
Syposs, Chauncey R.
Zent, Clive S.
Source :
Leukemia Research. May2023, Vol. 128, pN.PAG-N.PAG. 1p.
Publication Year :
2023

Abstract

Splenic B-cell lymphomas are rare and understudied entities. Splenectomy is frequently required for specific pathological diagnosis in patients with splenic B-cell lymphomas other than classical hairy cell leukemia (cHCL), and can be effective and durable therapy. Our study investigated the diagnostic and therapeutic role of splenectomy for non-cHCL indolent splenic B-cell lymphomas. Observational study of patients with non-cHCL splenic B-cell lymphoma undergoing splenectomy between 1 August 2011 and 1 August 2021 at the University of Rochester Medical Center. The comparison cohort was patients categorized as having non-cHCL splenic B-cell lymphoma who did not undergo splenectomy. Forty-nine patients (median age 68 years) had splenectomy (SMZL n = 33, HCLv n = 9, SDRPL n = 7) with median follow up of 3.9 years post splenectomy. One patient had fatal post-operative complications. Post-operative hospitalization was ≤ 4 days for 61% and ≤ 10 days for 94% of patients. Splenectomy was initial therapy for 30 patients. Of the 19 patients who had previous medical therapy, splenectomy changed their lymphoma diagnosis in 5 (26%). Twenty-one patients without splenectomy were clinically categorized as having non-cHCL splenic B-cell lymphoma. Nine required medical treatment for progressive lymphoma and of these 3 (33%) required re-treatment for lymphoma progression compared to 16% of patients following first line splenectomy. Splenectomy is useful for the diagnosis of non-cHCL splenic B-cell lymphomas with comparable risk/benefit profile and remission duration to medical therapy. Patients with suspected non-cHCL splenic lymphomas should be considered for referral to a high-volume center with experience in performing splenectomies for definitive diagnosis and treatment. ● Splenectomy is useful for definitive diagnosis of splenic B-cell lymphoma. ● Splenectomy has a comparable risk/benefit profile compared to medical therapy. ● Remission duration after splenectomy is comparable to medical therapy. ● Consider referral at clinical diagnosis to experienced surgical center. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01452126
Volume :
128
Database :
Academic Search Index
Journal :
Leukemia Research
Publication Type :
Academic Journal
Accession number :
163470037
Full Text :
https://doi.org/10.1016/j.leukres.2023.107053